- By country
- By industry
- By topic
- Top 100
ZAGREB (Croatia), October 22 (SeeNews) - Austria-based private equity firm Mezzanine Management-advised fund AMC IV has committed 10 million euro ($11.5 million) to support the growth of Croatian clinical research organisation Optimapharm, Mezzanine Management said on Monday.
The funds are earmarked for organic as well as acquisitive growth of Optimapharm and give the fund a minority stake in the business, Mezzanine Management said in an e-mailed statement.
The deal marks Mezzanine Management's entry into Croatia, the private equity firm said.
Chris Buckle, managing partner at Mezzanine Management, has joined Optimapharm's supervisory board as part of the deal.
"Run by an ambitious team of highly accomplished professionals, the business has grown rapidly to become the market leader in its core Adriatic region with an increasing footprint across the wider CEE and Western European regions. We have been in discussions with management for some time and already devised an exciting pipeline of accretive add-on opportunities, which we look forward to supporting, to help transform Optimapharm into a major independent European player," Buckle said.
Mezzanine Management is the exclusive advisor to the Accession Mezzanine Capital (AMC) group of funds, whose total investments exceed 600 million euro. Mezzanine Management has been operating in Central and Eastern Europe since 2001 through its offices in Vienna, Warsaw, Bucharest, Budapest and Prague. The funds' investment portfolio is diverse with 50 transactions over 12 countries in CEE.
($ = 0.869182 euro)